Koyfin Home > Directory > Health Care > Amicus Therapeutics > EBIT

Amicus Therapeutics EBIT Chart (FOLD)

Amicus Therapeutics annual/quarterly EBIT from 2006 to 2018. Earnings before interest and taxes measures the profit a company generates from its operations, making it synonymous with operating profit. By ignoring tax and interest expenses, it focuses solely on a company's ability to generate earnings from operations, ignoring variables such as the tax burden and capital structure.
  • Amicus Therapeutics EBIT for the quarter ending December 12, 2018 was $-69m a 20.04% decrease of -14m year over year
  • Amicus Therapeutics EBIT for the last 12 months ending December 12, 2018 was $-325m a 35.47% decrease of -115m year over year
  • Amicus Therapeutics Annual EBIT for 2018 was $-325m a 35.21% decrease of -115m from 2017
  • Amicus Therapeutics Annual EBIT for 2017 was $-211m a 16.99% decrease of -36m from 2016
  • Amicus Therapeutics Annual EBIT for 2016 was $-175m a 28.00% decrease of -49m from 2015
Other Income Statement Metrics:
  • Amicus Therapeutics EBITDA for the quarter ending December 12, 2018 was $-68m a 20.09% decrease of -14m year over year
  • Amicus Therapeutics Net Income for the quarter ending December 12, 2018 was $-78m a 36.07% decrease of -28m year over year
  • Amicus Therapeutics Total Revenue for the quarter ending September 09, 2018 was $21m a 28.49% increase of 6m year over year
View Chart On Koyfin

Quarterly FOLD EBIT Data

12/2018$-69m
09/2018$-155m
06/2018$-47m
03/2018$-55m
12/2017$-55m
09/2017$-54m
06/2017$-46m
03/2017$-47m
12/2016$-54m
09/2016$-43m

Annual FOLD EBIT Data

2018$-325m
2017$-211m
2016$-175m
2015$-126m
2014$-69m
2013$-62m
2012$-53m
2011$-50m
2010$-56m
2009$-6m